In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp
about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusClostridium innocuum Bacteremia in a patient with acquired immunodeficiency syndromeAntimicrobial resistance and susceptibility testing of anaerobic bacteriaUpdate on the emerging role of telavancin in hospital-acquired infectionsPropionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogenTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensTissue penetration of telavancin after intravenous administration in healthy subjects.Telavancin: a new lipoglycopeptide with multiple mechanisms of action.Clinical and microbiological characteristics of Eggerthella lenta bacteremiaProgress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureusTelavancin: a novel lipoglycopeptide for serious gram-positive infections.Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.New advances in the treatment of Clostridium difficile infection (CDI)Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Telavancin: a novel lipoglycopeptide antibiotic.Transplacental transfer of vancomycin and telavancinA comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.The times they are a-changin': new antibacterials for skin and skin structure infections.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.In vitro activity of telavancin against resistant gram-positive bacteria.Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium speciesActivity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.Corynebacterium jeikeium bacteraemia and pulmonary infiltrates in a patient with acute myelogenous leukaemia.Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic modelLife-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient.Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.Corynebacterium jeikeium endocarditis: A case report and comprehensive review of an underestimated infection.
P2860
Q24556635-0DF79144-B66F-403A-B868-065F97C02424Q24646673-ED2F746B-83DF-4DBE-9CE0-C818746BAC77Q26829185-C88756F7-29BE-42D8-806E-A04A1D58FFD5Q28083522-F9E029C7-5145-4F70-98ED-33A947EC96F3Q30407733-F2BF7C31-DCBF-41B0-8257-CB582CBA9F2BQ33788308-A2056048-3C01-4B53-B835-8939BECB3D40Q34352132-5756B03B-8CD5-4608-83A8-BA168E202A03Q34572923-F4B7A96D-3A3D-4FA2-9F5C-0B0477389943Q34983043-CD36968C-8547-430C-8FE2-FCB7DEC79807Q35044119-2EF4757A-F3E0-4FC3-823B-8B2ACEC05179Q35879100-1B65A2FA-FE9E-44B6-97D3-C79CF66261EEQ36736356-F4788614-B43C-4CF8-9199-6F2953AC882FQ36744770-F8D011B9-42B3-44CC-BC98-8455F635466CQ37052819-EBE529D1-BA6C-4474-AC05-AAB14F674A44Q37117865-1D9B4822-5AA5-470E-9106-A60D1C8A1077Q37252733-0AB66F8E-987B-4455-A868-9677AA2947A8Q37463589-C3283CAC-14C2-46B0-8960-F50CE3F54E37Q37478888-83E51451-93D7-48D8-A3CB-D4DFA0F26248Q37661510-E42E519B-3C46-413F-A8FC-D60B6D35A10FQ37955286-0DC147EB-38CD-4A0F-A1C7-E1673711CC93Q38438503-329C3C81-B5E4-4257-93F9-B18E73B97AD3Q38829519-DBE2F43E-AED1-4996-A54F-A80A5C21154FQ39686121-2B171E4C-F739-40D8-BE2B-7DBD430DEB70Q40189196-62AF3962-C1B5-465E-AFB7-1ADFA44EFAA8Q41028154-85B2F274-B0F8-4B50-8082-60DCACAF9771Q41780066-1A8694BE-A244-4DE8-90DE-0EFD8601B41AQ41950850-31253915-B5B2-4F33-B38E-1CFCEADF004DQ41954865-FF26F27A-7B26-45A8-A578-2B8277662ACAQ41999444-D49BD347-235A-40ED-889C-348F7C7D125AQ42266259-1406801E-B85A-490D-BDA1-2EC968E0E285Q42627265-7B082E5E-F125-4C42-8BF6-C32BD1DC77A6Q43097214-50F7545C-27A2-4157-B922-74C16C4141AFQ43184655-82B0AD5C-43D7-4F39-8328-7E96F694D835Q46489824-08FBD8F8-B7F2-45F6-B429-9814F190DF0DQ46634713-031FFEDA-C03C-4CF9-9CFC-F71F8818376FQ46689355-6649637D-1C73-4C9E-A33F-59CD369EE374Q54241643-B91116AB-CD63-46FE-87E6-3EFF56A3EB45
P2860
In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
In vitro activities of the new ...... pecies and Corynebacterium spp
@ast
In vitro activities of the new ...... pecies and Corynebacterium spp
@en
In vitro activities of the new ...... pecies and Corynebacterium spp
@nl
type
label
In vitro activities of the new ...... pecies and Corynebacterium spp
@ast
In vitro activities of the new ...... pecies and Corynebacterium spp
@en
In vitro activities of the new ...... pecies and Corynebacterium spp
@nl
prefLabel
In vitro activities of the new ...... pecies and Corynebacterium spp
@ast
In vitro activities of the new ...... pecies and Corynebacterium spp
@en
In vitro activities of the new ...... pecies and Corynebacterium spp
@nl
P2093
P2860
P1476
In vitro activities of the new ...... pecies and Corynebacterium spp
@en
P2093
C Vreni Merriam
Diane M Citron
Ellie J C Goldstein
Helen T Fernandez
Kerin L Tyrrell
Yumi A Warren
P2860
P304
P356
10.1128/AAC.48.6.2149-2152.2004
P407
P577
2004-06-01T00:00:00Z